Spruce Biosciences Performance
| SPRBDelisted Stock | USD 0.07 0.0004 0.56% |
The entity has a beta of -1.45, which indicates a somewhat significant risk relative to the market. As returns on the market increase, returns on owning Spruce Biosciences are expected to decrease by larger amounts. On the other hand, during market turmoil, Spruce Biosciences is expected to outperform it. At this point, Spruce Biosciences has a negative expected return of -4.73%. Please make sure to validate Spruce Biosciences' kurtosis, as well as the relationship between the day median price and period momentum indicator , to decide if Spruce Biosciences performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
Very Weak
Weak | Strong |
Over the last 90 days Spruce Biosciences has generated negative risk-adjusted returns adding no value to investors with long positions. Despite uncertain performance in the last few months, the Stock's basic indicators remain somewhat strong which may send shares a bit higher in August 2025. The current disturbance may also be a sign of long term up-swing for the company investors. ...more
| Begin Period Cash Flow | 96.4 M |
Spruce |
Spruce Biosciences Relative Risk vs. Return Landscape
If you would invest 13.00 in Spruce Biosciences on April 23, 2025 and sell it today you would lose (5.81) from holding Spruce Biosciences or give up 44.69% of portfolio value over 90 days. Spruce Biosciences is currently does not generate positive expected returns and assumes 13.1844% risk (volatility on return distribution) over the 90 days horizon. In different words, most equities are less risky than Spruce, and most traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Spruce Biosciences Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Spruce Biosciences' investment risk. Standard deviation is the most common way to measure market volatility of pink sheets, such as Spruce Biosciences, and traders can use it to determine the average amount a Spruce Biosciences' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.3588
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | SPRB |
Estimated Market Risk
| 13.18 actual daily | 96 96% of assets are less volatile |
Expected Return
| -4.73 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.36 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Spruce Biosciences is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Spruce Biosciences by adding Spruce Biosciences to a well-diversified portfolio.
Spruce Biosciences Fundamentals Growth
Spruce Pink Sheet prices reflect investors' perceptions of the future prospects and financial health of Spruce Biosciences, and Spruce Biosciences fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Spruce Pink Sheet performance.
| Return On Equity | -1.01 | ||||
| Return On Asset | -0.47 | ||||
| Operating Margin | (34.54) % | ||||
| Current Valuation | (32.9 M) | ||||
| Shares Outstanding | 42.2 M | ||||
| Price To Book | 0.11 X | ||||
| Price To Sales | 0.68 X | ||||
| Revenue | 4.91 M | ||||
| EBITDA | (56.15 M) | ||||
| Cash And Equivalents | 93.3 M | ||||
| Cash Per Share | 3.96 X | ||||
| Total Debt | 2.77 M | ||||
| Debt To Equity | 0.07 % | ||||
| Book Value Per Share | 0.68 X | ||||
| Cash Flow From Operations | (55.96 M) | ||||
| Earnings Per Share | (1.29) X | ||||
| Total Asset | 45.21 M | ||||
| Retained Earnings | (250.27 M) | ||||
About Spruce Biosciences Performance
By analyzing Spruce Biosciences' fundamental ratios, stakeholders can gain valuable insights into Spruce Biosciences' financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Spruce Biosciences has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Spruce Biosciences has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
Spruce Biosciences, Inc., a biopharmaceutical company, focuses on developing and commercializing novel therapies for rare endocrine disorders. Spruce Biosciences, Inc. was incorporated in 2014 and is headquartered in Daly City, California. Spruce Biosciences operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 17 people.Things to note about Spruce Biosciences performance evaluation
Checking the ongoing alerts about Spruce Biosciences for important developments is a great way to find new opportunities for your next move. Pink Sheet alerts and notifications screener for Spruce Biosciences help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Spruce Biosciences is not yet fully synchronised with the market data | |
| Spruce Biosciences generated a negative expected return over the last 90 days | |
| Spruce Biosciences has high historical volatility and very poor performance | |
| Spruce Biosciences has some characteristics of a very speculative penny stock | |
| Spruce Biosciences has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 4.91 M. Net Loss for the year was (53.04 M) with loss before overhead, payroll, taxes, and interest of (41.51 M). | |
| Spruce Biosciences currently holds about 93.3 M in cash with (55.96 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 3.96, which can makes it an attractive takeover target, given it will continue generating positive cash flow. |
- Analyzing Spruce Biosciences' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Spruce Biosciences' stock is overvalued or undervalued compared to its peers.
- Examining Spruce Biosciences' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Spruce Biosciences' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Spruce Biosciences' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Spruce Biosciences' pink sheet. These opinions can provide insight into Spruce Biosciences' potential for growth and whether the stock is currently undervalued or overvalued.
Check out World Market Map to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. You can also try the Portfolio Rebalancing module to analyze risk-adjusted returns against different time horizons to find asset-allocation targets.
Other Consideration for investing in Spruce Pink Sheet
If you are still planning to invest in Spruce Biosciences check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Spruce Biosciences' history and understand the potential risks before investing.
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities |